<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00808236</url>
  </required_header>
  <id_info>
    <org_study_id>BC-CP1012</org_study_id>
    <nct_id>NCT00808236</nct_id>
  </id_info>
  <brief_title>Pre-ROSC Intra-Nasal Cooling Effectiveness</brief_title>
  <acronym>PRINCE</acronym>
  <official_title>Trans-Nasal Cooling With the RhinoChill Device Following Cardiac Arrest: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BeneChill, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BeneChill, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study was to demonstrate the safety and feasibility of early intranasal
      cooling prior to return of spontaneous circulation (ROSC) in the emergency medical services
      (EMS) environment. It was hypothesized that cooling during the resuscitation attempt would
      increase ROSC and subsequent survival. The study was not powered to demonstrate
      statistically-significant differences in any outcome parameter, but was intended as an
      exploratory study only.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Out of hospital cardiac arrest remains a significant cause of death. Mild hypothermia induced
      after resuscitation from cardiac arrest has been shown to improve neurologically intact
      survival. Studies in dogs and rodents have demonstrated improved outcomes when cooling is
      initiated intra-arrest.

      The RhinoChill is a non-invasive cooling device through which rapid cooling is achieved via
      the intranasal delivery of an evaporative coolant into the nasopharynx. Due to its
      non-invasive and portable nature, the RhinoChill can be used to begin cooling earlier than
      other cooling devices.

      Studies performed using the RhinoChill in a porcine model of cardiac arrest suggest that
      cooling with the RhinoChill prior to the first defibrillation attempt facilitates
      resuscitation and improves resuscitation rate and neurologically intact survival.

      This study is being performed to assess the feasibility of using the RhinoChill device in the
      pre-hospital setting to improve resuscitation from cardiac arrest.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Achieve Return of Spontaneous Circulation (ROSC)</measure>
    <time_frame>1-hour after arrest</time_frame>
    <description>ROSC was defined as the return of an organized rhythm on electrocardiography (ECG) with a palpable pulse that was maintained for at least 20 minutes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Survived to Hospital Discharge</measure>
    <time_frame>30 days after arrest</time_frame>
    <description>The study end-point was hospital discharge. This outcome measure is the patient count for those that were discharged alive from the hospital.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Survived Neurologically-Intact</measure>
    <time_frame>30-days after arrest</time_frame>
    <description>The Cerebral Performance Categories (CPC) are used to describe neurological outcome. A CPC of 1 or 2 is considered &quot;neurologically intact.&quot;
- Good cerebral performance: little to no deficit.
- Moderate cerebral disability: capable of independent activities of daily life
- Severe cerebral disability: conscious, but dependent on others for daily support
- Coma or vegetative state
- Death or brain death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Primary Outcomes in Sub-group With VF/VT as First Rhythm</measure>
    <time_frame>hospital discharge</time_frame>
    <description>ROSC, survival, and neurologically-intact survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Therapeutic Temperature</measure>
    <time_frame>within 8 hours after enrollment</time_frame>
    <description>The therapeutic temperature range for treatment in cardiac arrest is considered to be 32-34C. Time to therapeutic temperature was taken as the first time in which 34C was measured. Tympanic and core temperatures were taken in all patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Stay</measure>
    <time_frame>Hospital Discharge</time_frame>
    <description>Length of stay data for patients admitted to the hospital will be calculated for:
Days on ventilator
Days in intensive care without ventilator
Days in general ward</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events (SAEs)</measure>
    <time_frame>7 days after arrest</time_frame>
    <description>These were defined serious adverse events that are not direct sequelae of the cardiac arrest itself or the underlying cardiac disease. Therefore, these do not include recurrent arrests occcuring within 24 hours of resuscitation nor deaths due to lack of cardiac and/or neurological recovery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24-hour Adverse Events (AE)</measure>
    <time_frame>24 hours after arrest</time_frame>
    <description>These were all non-serious adverse events that occurred between the time of enrollment and 24 hours after resuscitation. These did not include a failure to achieve ROSC.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Cardiac Arrest</condition>
  <arm_group>
    <arm_group_label>RhinoChill</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intra-arrest cooling with the RhinoChill during advanced cardiac life support</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Advanced cardiac life support, only</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RhinoChill</intervention_name>
    <description>Nasal catheters are placed and cooling is begun during the resuscitation attempt</description>
    <arm_group_label>RhinoChill</arm_group_label>
    <other_name>intra-nasal cooling</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Advanced cardiac life support according to American Heart Association &amp; European Resuscitation Council 2005 Guidelines</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  â‰¥18 years

          -  Collapse was witnessed

          -  No pulse

          -  Unresponsive to external stimuli

        Exclusion Criteria:

          -  Have an etiology of cardiac arrest due to trauma, severe bleeding, drug overdose (OD),
             cerebrovascular accident (CVA), drowning, smoke inhalation, electrocution, hanging

          -  Already hypothermic

          -  Head trauma

          -  Cannot place intra nasal catheters

          -  Do Not Attempt to Resuscitate (DNAR) orders

          -  Known or clinically apparent pregnancy

          -  Have a known coagulopathy (except therapeutically induced)

          -  Are known to have a need for supplemental oxygen

          -  Achieve return of spontaneous circulation (ROSC) prior to initiating cooling

          -  Are reached by emergency medical services (EMS) personnel more than 20 minutes after
             collapse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Denise Barbut, MD</last_name>
    <role>Study Chair</role>
    <affiliation>BeneChill, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU St Pierre</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasme Hospital (Free University of Brussels)</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Tivoli</name>
      <address>
        <city>La Louviere</city>
        <zip>7100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gasthuisberg Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR de la Citadelle</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helig Hartzieknehuis Roeselare</name>
      <address>
        <city>Roeselare</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Faculty Hospital KrÃ¡lovskÃ© Vinohrady</name>
      <address>
        <city>Prague</city>
        <zip>10034</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinisches Zentrum Kreis Aachen gGmbH</name>
      <address>
        <city>Aachen</city>
        <zip>52146</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite Campus Virchow Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Ludwigs University Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georg August-UniversitÃ¤t GÃ¶ttingen</name>
      <address>
        <city>GÃ¶ttingen</city>
        <zip>37086</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Martha-Maria Halle-DÃ¶lau gGmbH</name>
      <address>
        <city>Halle (Saale)</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otto-von-Guericke-UniversitÃ¤t Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O Ospedale San Gerardo di Monza</name>
      <address>
        <city>Monza</city>
        <zip>20052</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stockholm Prehospital Centrum</name>
      <address>
        <city>Stockholm</city>
        <zip>118 83</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Tsai MS, Barbut D, Tang W, Wang H, Guan J, Wang T, Sun S, Inderbitzen B, Weil MH. Rapid head cooling initiated coincident with cardiopulmonary resuscitation improves success of defibrillation and post-resuscitation myocardial function in a porcine model of prolonged cardiac arrest. J Am Coll Cardiol. 2008 May 20;51(20):1988-90. doi: 10.1016/j.jacc.2007.12.057.</citation>
    <PMID>18482670</PMID>
  </reference>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2008</study_first_submitted>
  <study_first_submitted_qc>December 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2008</study_first_posted>
  <results_first_submitted>May 21, 2010</results_first_submitted>
  <results_first_submitted_qc>June 18, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 16, 2010</results_first_posted>
  <last_update_submitted>June 8, 2011</last_update_submitted>
  <last_update_submitted_qc>June 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2011</last_update_posted>
  <responsible_party>
    <name_title>Becky Inderbitzen/Vice President Clinical Affairs</name_title>
    <organization>BeneChill</organization>
  </responsible_party>
  <keyword>Cardiac Arrest</keyword>
  <keyword>Pre-hospital</keyword>
  <keyword>Mild hypothermia</keyword>
  <keyword>Resuscitation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Arrest</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited by emergency medical system advanced life support personnel over an 8-month period (November 2008 through June 2009). Patients appearing to meet the study criteria were randomized during ongoing resuscitation procedures. Patients that survived to hospital admission were followed until death or hospital discharge.</recruitment_details>
      <pre_assignment_details>Due to the emergency nature of the research, patients were often randomized into the study before all exclusion criteria could be ruled out (e.g., &quot;Do Not Attempt to Resuscitate&quot; (DNAR) orders, drug over-dose (OD), cerebrovascular accident (CVA)). Therefore, patients meeting pre-defined exclusion criteria were not included in the outcome measures.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>RhinoChill</title>
          <description>Intra-arrest cooling with the RhinoChill during advanced cardiac life support</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>Advanced cardiac life support (ACLS), only. ACLS procedures were performed in accordance with the European Resuscitation Council 2006 Guidelines.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
                <participants group_id="P2" count="104"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Met Eligibility Criteria</title>
              <participants_list>
                <participants group_id="P1" count="84">Pre-defined exclusions: DNAR(4); had pulse(2); CVA(2); Drug OD(2); On home oxygen(1); Unwitnessed(1)</participants>
                <participants group_id="P2" count="101">Pre-defined exclusions: Terminal(1); Asphyxia(1), In-hospital(1)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Included in Analysis</title>
              <participants_list>
                <participants group_id="P1" count="83">Lost to Follow-Up: taken to non-participating hospital (1)</participants>
                <participants group_id="P2" count="99">Crossed over &amp; withdrawn (1); Lost to Follow-Up: taken to non-participating hospital (1)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Achieved ROSC</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Admitted to Hospital</title>
              <participants_list>
                <participants group_id="P1" count="30">Died during transport to hospital(2); DNAR determination was made at hospital(1)</participants>
                <participants group_id="P2" count="42">Died during transport to hospital(1)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="91"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Was not resuscitated</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="56"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pre-defined exclusion</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>RhinoChill</title>
          <description>Intra-arrest cooling with the RhinoChill during advanced cardiac life support</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>Advanced cardiac life support (ACLS), only. ACLS procedures were performed in accordance with the European Resuscitation Council 2006 Guidelines.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="96"/>
            <count group_id="B2" value="104"/>
            <count group_id="B3" value="200"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Overall number of participants included in analysis was 181: 82 RhinoChill patients and 99 Control patients</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.4" spread="13.2"/>
                    <measurement group_id="B2" value="64.8" spread="13.5"/>
                    <measurement group_id="B3" value="65" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Czech Republic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Bystander CPR</title>
          <description>The is the number of those participants that received bystander rescue cardiopulmonary resuscitation (CPR) efforts prior to the arrival of emergency medical service (EMS) personnel</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Received bystander CPR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did not receive bystander CPR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Evaluable Participants</title>
          <description>Eligible participants were those included in the analyses. These excluded those particiapnts found not meet all of the inclusion criteria or to have a pre-defined exclsion criteria as well as those lost to follow-up for whom no data was obtained.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Did not meet all Inclusion/Exclusion Criteria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No data obtained</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total evaluable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>First Rhythm</title>
          <description>First rhythm was defined as ventricular fibrillation/non-perfusing ventricular tacchycardia (VF/VT), asystole, or pulseless electrical activity/electro-mechanical dissociation (PEA/EMD)</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>VF/VT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asystole</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PEA/EMD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Elapsed time from collapse until:</title>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <title>EMS CPR Initiated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8" lower_limit="5" upper_limit="10"/>
                    <measurement group_id="B2" value="8" lower_limit="5" upper_limit="10"/>
                    <measurement group_id="B3" value="8" lower_limit="5" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>First Defibrillation Shock (VF only)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12" lower_limit="8" upper_limit="14"/>
                    <measurement group_id="B2" value="12" lower_limit="7" upper_limit="16"/>
                    <measurement group_id="B3" value="12" lower_limit="8" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Advanced Life Support (ALS) Arrived</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12" lower_limit="9" upper_limit="16"/>
                    <measurement group_id="B2" value="11" lower_limit="8" upper_limit="16"/>
                    <measurement group_id="B3" value="12" lower_limit="9" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intravenous (IV) Access Acquired</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16" lower_limit="14" upper_limit="20"/>
                    <measurement group_id="B2" value="15" lower_limit="12" upper_limit="20"/>
                    <measurement group_id="B3" value="16" lower_limit="12" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Airway Protected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18" lower_limit="14" upper_limit="22"/>
                    <measurement group_id="B2" value="16" lower_limit="12" upper_limit="20"/>
                    <measurement group_id="B3" value="17" lower_limit="13" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Randomized</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20" lower_limit="16" upper_limit="25"/>
                    <measurement group_id="B2" value="18" lower_limit="14" upper_limit="22"/>
                    <measurement group_id="B3" value="19" lower_limit="15" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cooling Initiated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23" lower_limit="18" upper_limit="30"/>
                    <measurement group_id="B2" value="113" lower_limit="71" upper_limit="200"/>
                    <measurement group_id="B3" value="30" lower_limit="20" upper_limit="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ROSC Achieved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32" lower_limit="29" upper_limit="38"/>
                    <measurement group_id="B2" value="30" lower_limit="22" upper_limit="38"/>
                    <measurement group_id="B3" value="31" lower_limit="23" upper_limit="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arrived at Hospital</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59" lower_limit="51" upper_limit="75"/>
                    <measurement group_id="B2" value="60" lower_limit="42" upper_limit="70"/>
                    <measurement group_id="B3" value="60" lower_limit="45" upper_limit="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Achieve Return of Spontaneous Circulation (ROSC)</title>
        <description>ROSC was defined as the return of an organized rhythm on electrocardiography (ECG) with a palpable pulse that was maintained for at least 20 minutes.</description>
        <time_frame>1-hour after arrest</time_frame>
        <population>Only patients meeting all inclusion/exclusion criteria (IC/EC) were included in the analyses. 15 patients were found to not meet all IC/EC after enrollment. 2 more patients were lost to follow-up and 1 patient was crossed over (Control to RhinoChill) and then withdrawn. Informed consent nor data was obtained for any of these patients.</population>
        <group_list>
          <group group_id="O1">
            <title>RhinoChill</title>
            <description>Intra-arrest cooling with the RhinoChill during advanced cardiac life support</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Advanced cardiac life support (ACLS), only. ACLS procedures were performed in accordance with the European Resuscitation Council 2006 Guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Achieve Return of Spontaneous Circulation (ROSC)</title>
          <description>ROSC was defined as the return of an organized rhythm on electrocardiography (ECG) with a palpable pulse that was maintained for at least 20 minutes.</description>
          <population>Only patients meeting all inclusion/exclusion criteria (IC/EC) were included in the analyses. 15 patients were found to not meet all IC/EC after enrollment. 2 more patients were lost to follow-up and 1 patient was crossed over (Control to RhinoChill) and then withdrawn. Informed consent nor data was obtained for any of these patients.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Survived to Hospital Discharge</title>
        <description>The study end-point was hospital discharge. This outcome measure is the patient count for those that were discharged alive from the hospital.</description>
        <time_frame>30 days after arrest</time_frame>
        <population>The set of patients excluding those not meeting IC/EC, not lost to follow-up, or not crossed-over/withdrawn. One RhinoChill patient that achieved ROSC was found to be &quot;DNAR&quot; upon hospital arrival and was excluded from analyses thereafter. The final number of analyzed RhinoChill patients was therefore 82.</population>
        <group_list>
          <group group_id="O1">
            <title>RhinoChill</title>
            <description>Intra-arrest cooling with the RhinoChill during advanced cardiac life support</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Advanced cardiac life support (ACLS), only. ACLS procedures were performed in accordance with the European Resuscitation Council 2006 Guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Survived to Hospital Discharge</title>
          <description>The study end-point was hospital discharge. This outcome measure is the patient count for those that were discharged alive from the hospital.</description>
          <population>The set of patients excluding those not meeting IC/EC, not lost to follow-up, or not crossed-over/withdrawn. One RhinoChill patient that achieved ROSC was found to be &quot;DNAR&quot; upon hospital arrival and was excluded from analyses thereafter. The final number of analyzed RhinoChill patients was therefore 82.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Survived Neurologically-Intact</title>
        <description>The Cerebral Performance Categories (CPC) are used to describe neurological outcome. A CPC of 1 or 2 is considered &quot;neurologically intact.&quot;
- Good cerebral performance: little to no deficit.
- Moderate cerebral disability: capable of independent activities of daily life
- Severe cerebral disability: conscious, but dependent on others for daily support
- Coma or vegetative state
- Death or brain death</description>
        <time_frame>30-days after arrest</time_frame>
        <population>The set of patients excluding those not meeting IC/EC, not lost to follow-up, or not crossed-over/withdrawn.</population>
        <group_list>
          <group group_id="O1">
            <title>RhinoChill</title>
            <description>Intra-arrest cooling with the RhinoChill during advanced cardiac life support</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Advanced cardiac life support (ACLS), only. ACLS procedures were performed in accordance with the European Resuscitation Council 2006 Guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Survived Neurologically-Intact</title>
          <description>The Cerebral Performance Categories (CPC) are used to describe neurological outcome. A CPC of 1 or 2 is considered &quot;neurologically intact.&quot;
- Good cerebral performance: little to no deficit.
- Moderate cerebral disability: capable of independent activities of daily life
- Severe cerebral disability: conscious, but dependent on others for daily support
- Coma or vegetative state
- Death or brain death</description>
          <population>The set of patients excluding those not meeting IC/EC, not lost to follow-up, or not crossed-over/withdrawn.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Primary Outcomes in Sub-group With VF/VT as First Rhythm</title>
        <description>ROSC, survival, and neurologically-intact survival</description>
        <time_frame>hospital discharge</time_frame>
        <population>Subset of all included patients with VF/VT as the first cardiac rhythm present upon ECG assessment by EMS personnel</population>
        <group_list>
          <group group_id="O1">
            <title>RhinoChill</title>
            <description>Intra-arrest cooling with the RhinoChill during advanced cardiac life support</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Advanced cardiac life support (ACLS), only. ACLS procedures were performed in accordance with the European Resuscitation Council 2006 Guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Outcomes in Sub-group With VF/VT as First Rhythm</title>
          <description>ROSC, survival, and neurologically-intact survival</description>
          <population>Subset of all included patients with VF/VT as the first cardiac rhythm present upon ECG assessment by EMS personnel</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Achieved ROSC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Survived to Hospital Discharge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Survived Neurologically-Intact</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Therapeutic Temperature</title>
        <description>The therapeutic temperature range for treatment in cardiac arrest is considered to be 32-34C. Time to therapeutic temperature was taken as the first time in which 34C was measured. Tympanic and core temperatures were taken in all patients.</description>
        <time_frame>within 8 hours after enrollment</time_frame>
        <population>The subset of patients that were resuscitated and subsequently received in-hospital cooling and reached the designated therapuetic temperatures.</population>
        <group_list>
          <group group_id="O1">
            <title>RhinoChill</title>
            <description>Intra-arrest cooling with the RhinoChill during advanced cardiac life support</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Advanced cardiac life support (ACLS), only. ACLS procedures were performed in accordance with the European Resuscitation Council 2006 Guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Therapeutic Temperature</title>
          <description>The therapeutic temperature range for treatment in cardiac arrest is considered to be 32-34C. Time to therapeutic temperature was taken as the first time in which 34C was measured. Tympanic and core temperatures were taken in all patients.</description>
          <population>The subset of patients that were resuscitated and subsequently received in-hospital cooling and reached the designated therapuetic temperatures.</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Time to 34C Tympanic Temperature</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102" lower_limit="81" upper_limit="155"/>
                    <measurement group_id="O2" value="291" lower_limit="183" upper_limit="416"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time to 34C Core Temperature</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155" lower_limit="124" upper_limit="315"/>
                    <measurement group_id="O2" value="284" lower_limit="172" upper_limit="471"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time to 33C Tympanic Temperature</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="170" lower_limit="101" upper_limit="335"/>
                    <measurement group_id="O2" value="377" lower_limit="258" upper_limit="635"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time to 33C Core Temperature</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="315" lower_limit="180" upper_limit="477"/>
                    <measurement group_id="O2" value="389" lower_limit="280" upper_limit="649"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Stay</title>
        <description>Length of stay data for patients admitted to the hospital will be calculated for:
Days on ventilator
Days in intensive care without ventilator
Days in general ward</description>
        <time_frame>Hospital Discharge</time_frame>
        <population>Evaluable patients admitted to the hospital</population>
        <group_list>
          <group group_id="O1">
            <title>RhinoChill</title>
            <description>Intra-arrest cooling with the RhinoChill during advanced cardiac life support</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Advanced cardiac life support (ACLS), only. ACLS procedures were performed in accordance with the European Resuscitation Council 2006 Guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Stay</title>
          <description>Length of stay data for patients admitted to the hospital will be calculated for:
Days on ventilator
Days in intensive care without ventilator
Days in general ward</description>
          <population>Evaluable patients admitted to the hospital</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-survivors</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="2.3" upper_limit="5.4"/>
                    <measurement group_id="O2" value="2.6" lower_limit="0.3" upper_limit="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Survivors - ventilator days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" lower_limit="3.0" upper_limit="5.8"/>
                    <measurement group_id="O2" value="8.8" lower_limit="5.2" upper_limit="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Survivors - ICU days (no ventilator)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="0.6" upper_limit="6.5"/>
                    <measurement group_id="O2" value="3.0" lower_limit="2.0" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Survivors - general ward days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8" lower_limit="7.0" upper_limit="20"/>
                    <measurement group_id="O2" value="11.5" lower_limit="7.0" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Primary Outcomes in Sub-group Receiving EMS CPR Within 10 Minutes of Collapse</title>
        <description>ROSC, Survival, and neurologically-intact survival</description>
        <time_frame>Hospital discharge</time_frame>
        <population>Subset of patients receiving EMS CPR within 10 minutes of collapse (representing 75% of all patients)</population>
        <group_list>
          <group group_id="O1">
            <title>RhinoChill</title>
            <description>Intra-arrest cooling with the RhinoChill during advanced cardiac life support</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Advanced cardiac life support (ACLS), only. ACLS procedures were performed in accordance with the European Resuscitation Council 2006 Guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Outcomes in Sub-group Receiving EMS CPR Within 10 Minutes of Collapse</title>
          <description>ROSC, Survival, and neurologically-intact survival</description>
          <population>Subset of patients receiving EMS CPR within 10 minutes of collapse (representing 75% of all patients)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Achieved ROSC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Survived to Hospital Discharge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Survived Neurologically-Intact</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serious Adverse Events (SAEs)</title>
        <description>These were defined serious adverse events that are not direct sequelae of the cardiac arrest itself or the underlying cardiac disease. Therefore, these do not include recurrent arrests occcuring within 24 hours of resuscitation nor deaths due to lack of cardiac and/or neurological recovery.</description>
        <time_frame>7 days after arrest</time_frame>
        <population>All enrolled patients; see additional modified &quot;at risk&quot; population based on study attrition in the Adverse Event section.</population>
        <group_list>
          <group group_id="O1">
            <title>RhinoChill</title>
            <description>Intra-arrest cooling with the RhinoChill during advanced cardiac life support</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Advanced cardiac life support (ACLS), only. ACLS procedures were performed in accordance with the European Resuscitation Council 2006 Guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Serious Adverse Events (SAEs)</title>
          <description>These were defined serious adverse events that are not direct sequelae of the cardiac arrest itself or the underlying cardiac disease. Therefore, these do not include recurrent arrests occcuring within 24 hours of resuscitation nor deaths due to lack of cardiac and/or neurological recovery.</description>
          <population>All enrolled patients; see additional modified &quot;at risk&quot; population based on study attrition in the Adverse Event section.</population>
          <units>all participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>24-hour Adverse Events (AE)</title>
        <description>These were all non-serious adverse events that occurred between the time of enrollment and 24 hours after resuscitation. These did not include a failure to achieve ROSC.</description>
        <time_frame>24 hours after arrest</time_frame>
        <population>all enrolled participants</population>
        <group_list>
          <group group_id="O1">
            <title>RhinoChill</title>
            <description>Intra-arrest cooling with the RhinoChill during advanced cardiac life support</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Advanced cardiac life support (ACLS), only. ACLS procedures were performed in accordance with the European Resuscitation Council 2006 Guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>24-hour Adverse Events (AE)</title>
          <description>These were all non-serious adverse events that occurred between the time of enrollment and 24 hours after resuscitation. These did not include a failure to achieve ROSC.</description>
          <population>all enrolled participants</population>
          <units>all participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RhinoChill-related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Outcomes for Patients Admitted to the Hospital</title>
        <description>Suvival and neurologically intact survival</description>
        <time_frame>Hospital discharge</time_frame>
        <population>Subset of patients that achieved ROSC and were subsequently admitted to the hospital.</population>
        <group_list>
          <group group_id="O1">
            <title>RhinoChill</title>
            <description>Intra-arrest cooling with the RhinoChill during advanced cardiac life support</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Advanced cardiac life support (ACLS), only. ACLS procedures were performed in accordance with the European Resuscitation Council 2006 Guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Outcomes for Patients Admitted to the Hospital</title>
          <description>Suvival and neurologically intact survival</description>
          <population>Subset of patients that achieved ROSC and were subsequently admitted to the hospital.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Survived to Hospital Discharge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Survived Neurologically-Intact</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Outcomes for VF Patients Admitted to the Hospital</title>
        <description>Survival and neurologically-intact survival for patients found in VF/VT admitted to the hospital</description>
        <time_frame>Hospital discharge</time_frame>
        <population>Subset of patients with an initial rhythm of VF/VT, achieved ROSC and were subsequently admitted to the hospital</population>
        <group_list>
          <group group_id="O1">
            <title>RhinoChill</title>
            <description>Intra-arrest cooling with the RhinoChill during advanced cardiac life support</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Advanced cardiac life support (ACLS), only. ACLS procedures were performed in accordance with the European Resuscitation Council 2006 Guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Outcomes for VF Patients Admitted to the Hospital</title>
          <description>Survival and neurologically-intact survival for patients found in VF/VT admitted to the hospital</description>
          <population>Subset of patients with an initial rhythm of VF/VT, achieved ROSC and were subsequently admitted to the hospital</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All Survivors</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neurologically-Intact Survivors</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Outcomes for Patients Receiving EMS CPR Within 10 Minutes of Collapse That Were Admitted to the Hospital</title>
        <time_frame>Hospital Discharge</time_frame>
        <population>Subset of patients that received EMS CPR within 10 minutes of collapse, achieved ROSC, and were subsequently admitted to the hospital.</population>
        <group_list>
          <group group_id="O1">
            <title>RhinoChill</title>
            <description>Intra-arrest cooling with the RhinoChill during advanced cardiac life support</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Advanced cardiac life support (ACLS), only. ACLS procedures were performed in accordance with the European Resuscitation Council 2006 Guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Outcomes for Patients Receiving EMS CPR Within 10 Minutes of Collapse That Were Admitted to the Hospital</title>
          <population>Subset of patients that received EMS CPR within 10 minutes of collapse, achieved ROSC, and were subsequently admitted to the hospital.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Survived to Hospital Discharge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Survived Neurologically-Intact</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse events (SAEs) were collected over the first seven days after study enrollment. Other clinically significant adverse events were collected over the first 24 hours.</time_frame>
      <desc>Death was not considered to be an SAE, but the result of one. Failure to achieve return of spontaneous circulation was not considered to be an SAE. Additional events that did not qualify for reporting as SAEs were re-arrests occurring within 24 hours and deaths directly due to lack of cardiac or neurological recovery from the index event.</desc>
      <group_list>
        <group group_id="E1">
          <title>RhinoChill</title>
          <description>Intra-arrest cooling with the RhinoChill during advanced cardiac life support</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>Advanced cardiac life support (ACLS), only. ACLS procedures were performed in accordance with the European Resuscitation Council 2006 Guidelines.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6"/>
                <counts group_id="E2" subjects_affected="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding</sub_title>
                <description>Bleeding could occur from any orifice</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Myocardial Infarct</sub_title>
                <description>new; occurring more than 24 hours after hospitalization</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Lethal/long-lasting arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Sepsis/Multi-organ failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsions</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="96"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal discoloration</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Peri-orbital emphysema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Becky Inderbitzen, Vice President of Clincial Affairs</name_or_title>
      <organization>BeneChill, Inc.</organization>
      <phone>858-695-8118</phone>
      <email>binderbitzen@benechill.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

